Clinical Trials Browser

NIH × Interventional × Everolimus × Clear all

NCT05773274 2026-03-18

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Phase 2 Recruiting

Metastatic Digestive System Neuroendocrine Tumor G1

NCT04665739 2026-03-17

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Phase 2 Recruiting

Advanced Lung Neuroendocrine Tumor

NCT01827384 2023-09-29

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

Phase 2 Completed

208 enrolled 27 charts

Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT01229943 2022-08-04

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

Phase 2 Completed

150 enrolled 12 charts

Vipoma

NCT01434602 2022-06-01

Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas

Phase 1/2 Completed

86 enrolled 24 charts

Brain Neoplasms, Glioblastoma

NCT02315625 2020-09-09

Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery

Phase 2 Terminated

16 enrolled 15 charts

Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT01239342 2019-10-10

Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer

Phase 2 Terminated

43 enrolled 12 charts

Carcinoma, Renal Cell

NCT02504892 2019-03-22

Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer

Phase 2 Terminated

3 enrolled 7 charts

Kidney Neoplasms, Neoplastic Syndromes, Hereditary, Birt-Hogg-Dube Syndrome

NCT01198158 2019-03-06

Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy

Phase 3 Terminated

77 enrolled 11 charts

Carcinoma, Renal Cell

NCT01204476 2016-07-15

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Phase 1 Completed

CNSDermatologicEndocrine

Glucagonoma, Insulinoma, Paraganglioma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary

NCT01281865 2014-10-08

Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma

Phase 1/2 Completed

14 enrolled 7 charts

Sarcoma, Sarcoma, Synovial

NCT00544999 2013-09-17

Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia

Phase 1 Unknown

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT01118065 2013-08-12

Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer

Phase 2 Unknown

EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Thyroid Carcinoma, Anaplastic